Medigen Vaccine Biologics

Charles River Laboratories International and Medigen Vaccine Biologics Corp. announced a collaboration to characterize and validate the virus seed bank for Medigen's next-generation multivalent enterovirus vaccine. Charles River will provide advanced analytical support including Next-Generation Sequencing for key Chemistry, Manufacturing, and Controls activities. The partnership highlights Charles River's role as a specialized partner for complex biologics testing and regulatory readiness, potentially reinforcing its positioning in high-value vaccine and infectious disease programs. The collaboration slots into an existing narrative of expanding capabilities in biologics and infectious disease work rather than resetting expectations on its own.